Showing results (91-100 of 198) with videos related to
Sort By:
Pageof 20
Journal of the American College of Cardiology|August 9, 2014
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trialChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.JAMA Cardiology|October 19, 2022
Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-ITSiddharth M Patel, Arman Qamar, Robert P Giugliano, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|January 15, 2021
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trialSarah E Nelson, Robert P Giugliano, Elliott M Antman, et al.European Heart Journal|February 18, 2015
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†Michelle L O'Donoghue, Christian T Ruff, Robert P Giugliano, et al.Circulation|October 11, 2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 TrialBrian A Bergmark, Pieter W Kamphuisen, Stephen D Wiviott, et al.JAMA Cardiology|July 10, 2024
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialAndré Zimerman, Eugene Braunwald, Jan Steffel, et al.Circulation. Arrhythmia and Electrophysiology|January 13, 2017
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)Mark S Link, Robert P Giugliano, Christian T Ruff, et al.Journal of the American Heart Association|October 30, 2018
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 TrialChristina L Fanola, Christian T Ruff, Sabina A Murphy, et al.Journal of the American Heart Association|July 2, 2017
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 TrialAlon Eisen, Christian T Ruff, Eugene Braunwald, et al.European Heart Journal. Cardiovascular Pharmacotherapy|November 6, 2019
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trialAndré M Nicolau, Ramon Corbalan, Jose C Nicolau, et al.Pageof 20